Fresenius Kabi launches generic Mozobil

Fresenius Kabi is debuting Plerixafor injection, which is a generic of Sanofi’s Mozobil.

The product is available immediately in a 24 mg per 1.2 ml single-dose vial.

Plerixafor injection is a hematopoietic stem cell mobilizer used in combination with granulocyte-colony stimulating factor in patients with non-Hodgkin's lymphoma or multiple myeloma.

[Read more: Fresenius Kabi intros generic Foscavir]

"Fresenius Kabi is pleased to add Plerixafor injection to our oncology portfolio, further demonstrating our commitment to expanding access to high-quality and cost-effective oncology medicines in the United States,” said John Ducker, president and CEO of Fresenius Kabi USA. “The introduction of this generic equivalent will provide patients and clinicians with access to more choices for their cancer care.”

[Read more: Fresenius Kabi intros generic Foscavir]